ArticleMolecules (Basel, Switzerland)2019
Systematic Identification of Thiosemicarbazides for Inhibition of
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Dermatophyte-Selective Imidazole-Thiosemicarbazides: Potent In Vitro Activity AgainstInternational journal of molecular sciences · 2025Article
- In Vivo Safety and Efficacy of Thiosemicarbazones in Experimental Mice Infected withBiomedicines · 2025Article
- Transient Adaptation ofInternational journal of molecular sciences · 2024Article
- TZD-Based Hybrid Molecules Act as Dual Anti-International journal of molecular sciences · 2023Article
- X-ray Structures and Computational Studies of Two Bioactive 2-(Adamantane-1-carbonyl)-Molecules (Basel, Switzerland) · 2022Article
- Inhibition ofJournal of enzyme inhibition and medicinal chemistry · 2022Article
- 4-Arylthiosemicarbazide Derivatives as Toxoplasmic Aromatic Amino Acid Hydroxylase Inhibitors and Anti-inflammatory Agents.International journal of molecular sciences · 2022Article
- The Current Directions of Searching for Antiparasitic Drugs.Molecules (Basel, Switzerland) · 2022Review
- Article
- 4-Arylthiosemicarbazide derivatives as a new class of tyrosinase inhibitors and anti-Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Article
- Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.Molecules (Basel, Switzerland) · 2020Article
- Synthesis and Anthelmintic Activity of New Thiosemicarbazide Derivatives-A Preliminary Study.Molecules (Basel, Switzerland) · 2020Article
- Synthesis and In Vitro Anti-Molecules (Basel, Switzerland) · 2019Article
- Discovery of Potent and Selective Halogen-Substituted Imidazole-Thiosemicarbazides for Inhibition ofMolecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the key stages in the development of new therapies in the treatment of toxoplasmosis is the identification of new non-toxic small molecules with high specificity to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.